CortagenvsNAD+

Cortagen (Ala-Glu-Asp-Pro) is a synthetic tetrapeptide belonging to the Khavinson family of peptide bioregulators — short peptides proposed to regulate gene expression in a tissue-specific manner. The bioregulator hypothesis, developed by Professor Vladimir Khavinson over decades of research at the St. Petersburg Institute of Bioregulation and Gerontology, proposes that short peptides (2-4 amino acids) can penetrate cell membranes and nuclear envelopes, interact directly with DNA in a sequence-specific manner, and modulate transcription of tissue-relevant genes.

Cortagen is specifically designed to target neurons of the cerebral cortex. According to the Khavinson model, the AEDP tetrapeptide sequence has complementarity to specific DNA sequences in gene promoter regions active in cortical neurons. Upon binding to these regulatory elements, Cortagen is proposed to modulate chromatin structure and transcription factor access, influencing the expression of genes involved in neuronal function, synaptic transmission, antioxidant defense, and protein synthesis. The tissue specificity — cortex rather than other brain regions or body tissues — is attributed to the unique chromatin accessibility and transcription factor environment in cortical neurons that determines which genes are available for regulation.

Preclinical studies from Russian research programs have reported that Cortagen treatment improves cognitive function, enhances learning and memory, and provides neuroprotection in models of cerebral ischemia and age-related cognitive decline. The proposed mechanism involves restoration of age-related declines in protein synthesis in cortical neurons, enhancement of antioxidant enzyme expression (SOD, catalase, GPx), and improved synaptic function through upregulation of synaptophysin and other synaptic proteins. It should be noted that the peptide bioregulator field remains controversial in Western pharmacology — while the Russian research program is extensive, the proposed direct DNA-binding mechanism has not been independently validated through the standard molecular biology methods expected in Western peer-reviewed literature.

Nicotinamide Adenine Dinucleotide (NAD+) is a dinucleotide coenzyme consisting of nicotinamide mononucleotide (NMN) joined to adenosine monophosphate (AMP) through a pyrophosphate bond. It exists in oxidized (NAD+) and reduced (NADH) forms and participates in over 500 enzymatic reactions, making it one of the most central molecules in cellular metabolism.

As a redox cofactor, NAD+ accepts hydride ions (H-) during catabolic reactions. In glycolysis, the TCA cycle, and fatty acid beta-oxidation, NAD+ is reduced to NADH, which then donates electrons to Complex I of the mitochondrial electron transport chain, driving oxidative phosphorylation and ATP production. Without adequate NAD+, the entire energy production machinery of the cell grinds to a halt.

Equally important are NAD+'s roles as a consumed substrate for three families of signaling enzymes. Sirtuins (SIRT1-7) are NAD+-dependent protein deacylases and ADP-ribosyltransferases that use NAD+ as a co-substrate, cleaving it to nicotinamide and O-acetyl-ADP-ribose during the deacetylation reaction. SIRT1 and SIRT3 are particularly important for aging — SIRT1 deacetylates PGC-1α (activating mitochondrial biogenesis), FOXO transcription factors (activating stress resistance), and NF-κB (suppressing inflammation). SIRT3 in the mitochondrial matrix activates SOD2 and other mitochondrial enzymes. PARPs (poly-ADP-ribose polymerases) consume NAD+ during DNA damage repair, adding chains of ADP-ribose to histones near DNA breaks to recruit repair machinery. CD38, an NAD+-consuming glycohydrolase on immune cells, regulates calcium signaling and immune activation.

NAD+ levels decline 40-60% between ages 40 and 70, driven by increased CD38 expression (with chronic low-grade inflammation), increased PARP activity (from accumulated DNA damage), and reduced synthesis (decreased NAMPT enzyme activity). This decline impairs sirtuin function, reduces ATP production, compromises DNA repair, and contributes to virtually every hallmark of aging. Supplementation strategies aim to restore NAD+ levels either directly (IV infusion) or through biosynthetic precursors: NMN enters the salvage pathway one step from NAD+, while NR (nicotinamide riboside) requires an additional phosphorylation step.